Background Dabigatran is an oral direct thrombin inhibitor for which routine laboratory
monitoring is currently not recommended. However, there are situations in which …

Ways to monitor dabigatran etexilate (DE) therapy would be useful in certain situations.
Functional assays such as aPTT or Hemoclot® Thrombin Inhibitor (HTI) have been …

Objectives: To study dabigatran etexilate, a new oral anticoagulant that functions as a direct
thrombin inhibitor. Methods: This study evaluates four methods, one of which is performed in …

Background: Dabigatran etexilate is a new oral anticoagulant for the therapy and
prophylaxis of venous thromboembolism and stroke prevention in patients with atrial …

Background Knowledge of anticoagulation status during dabigatran therapy may be
desirable in certain clinical situations. Objective To determine the coagulation tests that are …

Background Direct oral anticoagulant dabigatran was first introduced as a fixed-dose drug
without routine coagulation monitoring, but current recommendations suggest that diluted …

Dabigatran, a new direct thrombin inhibitor, achieves strong anticoagulation that is more
predictable than warfarin. Nevertheless, a patient on dabigatran therapy (DT) may suffer …

Routine laboratory monitoring is currently not recommended in patients receiving dabigatran
despite its considerable variation in plasma concentration. However, in certain clinical …

Introduction The oral direct thrombin inhibitor dabigatran is increasingly used to prevent
thromboembolic stroke in patients with atrial fibrillation (AF). Routine laboratory monitoring is …

Due to low bioavailability and high inter-individual variability, monitoring of dabigatran may
be required in specific situations to prevent the risk of bleedings or thrombosis. The aim of …